212 related articles for article (PubMed ID: 37092128)
21. Notch signaling mutations increase intra-tumor chemokine expression and predict response to immunotherapy in colorectal cancer.
Wang F; Huang C; Long J; Zhao ZB; Ma HQ; Yao XQ; Li L; Lian ZX
BMC Cancer; 2022 Aug; 22(1):933. PubMed ID: 36038820
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the notch signalling pathway are associated with enhanced anti-tumour immunity in colorectal cancer.
Wang F; Long J; Li L; Zhao ZB; Wei F; Yao Y; Qiu WJ; Wu ZX; Luo QQ; Liu W; Quan YB; Lian ZX; Cao J
J Cell Mol Med; 2020 Oct; 24(20):12176-12187. PubMed ID: 32924269
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma.
Lin X; Wang L; Xie X; Qin Y; Xie Z; Ouyang M; Zhou C
Front Mol Biosci; 2020; 7():602328. PubMed ID: 33330629
[TBL] [Abstract][Full Text] [Related]
24. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
25. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
[TBL] [Abstract][Full Text] [Related]
26. The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Sun Y; Yang Q; Shen J; Wei T; Shen W; Zhang N; Luo P; Zhang J
Front Cell Dev Biol; 2021; 9():745859. PubMed ID: 34660603
[No Abstract] [Full Text] [Related]
27. The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract][Full Text] [Related]
28. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
Front Immunol; 2021; 12():646874. PubMed ID: 33927719
[TBL] [Abstract][Full Text] [Related]
29. Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma.
Liu R; Liang W; Hua Q; Wu L; Wang X; Li Q; Zhong F; Li B; Qiu Z
Front Immunol; 2022; 13():819515. PubMed ID: 35251000
[TBL] [Abstract][Full Text] [Related]
30. MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L; Li M; Deng L; Niu Y; Tang Y; Wang Y; Guo L
Front Pharmacol; 2021; 12():625593. PubMed ID: 33927616
[No Abstract] [Full Text] [Related]
31. Effect of mesenchymal-epithelial transition amplification on immune microenvironment and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer.
Su S; Lin A; Luo P; Zou J; Huang Z; Wang X; Zeng Y; Cen W; Zhang X; Huang H; Hu J; Zhang J
Ann Transl Med; 2021 Sep; 9(18):1475. PubMed ID: 34734027
[TBL] [Abstract][Full Text] [Related]
32. Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy
Lanuza PM; Alonso MH; Hidalgo S; Uranga-Murillo I; García-Mulero S; Arnau R; Santos C; Sanjuan X; Santiago L; Comas L; Redrado S; Pazo-Cid R; Agustin-Ferrández MJ; Jaime-Sánchez P; Pesini C; Gálvez EM; Ramírez-Labrada A; Arias M; Sanz-Pamplona R; Pardo J
Front Immunol; 2022; 13():890836. PubMed ID: 35747143
[TBL] [Abstract][Full Text] [Related]
33.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
34. Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma.
Ying H; Lin A; Liang J; Zhang J; Luo P
Front Mol Biosci; 2021; 8():629330. PubMed ID: 34113648
[TBL] [Abstract][Full Text] [Related]
35. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
36. Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC.
Zhang Z; Gu Y; Su X; Bai J; Guan W; Ma J; Luo J; He J; Zhang B; Geng M; Xia X; Guan Y; Shen C; Chen C
Front Oncol; 2021; 11():659321. PubMed ID: 33968765
[TBL] [Abstract][Full Text] [Related]
37. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
38. Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration.
Guan R; Lyu Q; Lin A; Liang J; Ding W; Cao M; Luo P; Zhang J
Front Oncol; 2021; 11():670927. PubMed ID: 34249711
[TBL] [Abstract][Full Text] [Related]
39. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
40. Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.
Feng W; Lin A; Sun L; Wei T; Ying H; Zhang J; Luo P; Zhu W
Cancer Cell Int; 2022 May; 22(1):186. PubMed ID: 35562800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
